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I. Abstract 
Fibroblast Growth Factors (FGFs) play important roles in the processes of the inner ear, 
and more specifically, in early otic induction. However, the detailed cellular signaling 
mechanisms underlying FGF-FGF receptor (FGFR) dependent otic specification remain 
elusive. To our knowledge, we have pursued the first attempts in devising a protocol that 
may optimize the use of FGFs on H7 stem cell-derived pre-placodal cells to maximize 
downstream activation of the ERK pathway, known to be important for the up-regulation 
of otic markers. By means of the Validation Protocol Assays, we determined the 
experimental conditions necessary for activation of canonical pathways, ERK, AKT, and 
PLCγ, downstream of FGF signaling. However, when the experimental scheme was 
translated to our specified otic differentiation protocol, the Contextual Culture Paradigm, 
no visible changes in phosphorylation were detected, despite the presence of FGFRs in 
the cells. This study discusses the results and their relevance in exploring the unidentified 
activity of downstream signaling pathways that cooperate with FGFs in inducing otic 
progenitor-like cells. Potential reasons for the absence of detectable downstream 
activation and future directions for study are discussed.   
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II. Introduction and Background 
a. General Introduction 
About seventeen percent of Americans have varying degrees of hearing loss that 
cannot be cured, according to the Harvard Stem Cell Institute. The more severe stages of 
hearing loss affect those older than sixty-five years of age, and this population makes up 
a large percentage of all Americans who suffer irreversible hearing loss (Harvard Stem 
Cell Institute). Stem cell scientists aim to bring hearing back for such patients. Humans 
are born with a specific number of hair cells in each ear, and they are susceptible to 
permanent damage by factors including noise trauma, toxic substances, aging, and 
disease (Harvard Stem Cell Institute). Strategies to bypass the disabilities of hearing loss 
with the use of hearing aids and cochlear implants are in place; however, to truly recover 
the loss of sensory neurons and poor biological function of the inner ear, the underlying 
neural circuitry must be reestablished. Scientists are working to develop treatments for 
hearing loss and related impairments with the use of stem cell-derived hair cells that may 
be grown in in vitro, and subsequently, implanted in the ear (Harvard Stem Cell 
Institute).  
 
b. Sensory Hair Cells 
The cochlea is a spiral-shaped structure, which serves as the hearing organ in 
mammals (Forge and Write, 2002). Figure 1 depicts the location of the cochlea, with 
respect to the external ear canal. The central chamber of the cochlea, also known as the 
cochlear duct, contains the organ of Corti (Figure 2), a structure that holds the sensory 
epithelium of the inner ear (Forge and Write, 2002). Figure 3 zooms in on its orderly 
structure, which consists of hair cells and supporting cells that sit on the flexible basilar 
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membrane (Forge and Write 2002). The two types of hair cells that populate the sensory 
epithelium, inner and outer hair cells, are unique in function. Figure 3 illustrates these 
structures – a single row of flask-shaped inner hair cells and three rows of cylindrical 
outer hair cells on the right (Forge and Write, 2002).   
 
 
 
 
Figure 1. Structure of the Ear.  
The cochlea (blue) is shown in the inner ear 
compartment. 
http://oto2.wustl.edu/cochlea/intro1.htm 
!
Figure 2. Cross-Sectional View of the 
Cochlea 
Lemasurier and Gillespie (2005) 
Figure 3. The Organ of Corti.  
Single row of flask-shaped inner hair cell on 
the right and three cylindrically shaped rows 
of outer hair cells on the left. 
https://www.bcm.edu/healthcare/care-
centers/otolaryngology/patient-information/how-ear-
works/organ-corti 
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The inner hair cells are solely innervated by afferent nerves, indicative of their 
true function in hearing. They convey the sensory stimulus from the cochlea to the brain, 
with synapses occurring at each inner hair cell (Forge and Write, 2002). Conversely, 
outer hair cells are innervated by many efferent neurons, as they serve a modular role in 
amplifying low-level sounds that enter the cochlea (Forge and Write, 2002). To re-
establish the neural circuitry impaired in hearing loss and related disease, it is important 
to target therapeutic strategies at the regeneration of inner ear hair cells. 
 
c. Stem Cell Differentiation 
Stem cells are critically important for living organisms. They give rise to distinct 
tissues and organs during the development of the organism, as well as replacements for 
specialized adult cells that may have undergone injury or disease (NIH, 2015). The 
unique regenerative ability that stem cells possess offers new potential for treating 
hearing loss and diseases that affect sensory hair cells. The human cochlea has only 3500 
inner ear hair cells (Kolb and Whishaw, 2003), and they are incapable of regeneration, 
deeply buried in the inner ear structures. Thus, in vitro stem cell differentiation methods 
may circumvent such issues and offer new avenues for study. 
Differentiation protocols involve the use of distinct types of stem cells. In this 
study, we perform experimentation with human embryonic stem cells (hESCs). The 
hESCs are transferred from a pre-implantation stage embryo into a laboratory culture 
dish. The hESCs divide, expand, and attach on the surface of coated dishes, which also 
contain a nutrient broth, known as culture medium. This defines the habitable condition 
in which the hESCs reside. As cells continue to grow and divide, they must be removed 
and re-suspended, or sub-cultured, onto freshly coated dishes, in order to inhibit 
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crowding or pre-mature differentiation. Cells are periodically sub-cultured, and each 
cycle is referred to as a passage. In this way, scientists may manipulate the self-renewable 
pool of cells by adding various molecules, drug treatments, and/or substrates, in 
adherence to a devised protocol that aims to drive cells towards a specific fate.  
 
Taking cues from developmental literature and related studies allows researchers 
to create optimal differentiation protocols that may derive sensory hair cells in a multi-
staged, methodical manner. The in vitro differentiation process begins with the formation 
of embryoid bodies (EBs) from undifferentiated hESC colonies (Figure 4). Due to their 
inherent characteristics as stem cell aggregates, EBs undergo stages similar to those that 
take place during embryogenesis. This provides a means of in vitro hESC differentiation 
into cell types of various fates (Kurosawa, 2007). By taking cues from literature on 
mammalian development, researchers apply growth factors, small molecules, drug 
treatments, and/or other components that may influence cells to acquire each stage of 
differentiation, in a the methodical manner. 
 
  
Figure 4. The Method of 
Stem Cell Differentiation  
(Yabut, 2011) 
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d. Sensory Placodes and Characteristic Marker Expression 
Scientists must understand the inherent cellular properties and the surrounding 
environments in which cells will best thrive and develop. Early in development, the 
mammalian head is divided into contextual regions of fated placodes, from which cells 
differentiate to take on specific identities (Sreit, 2008). As described by Larsen and 
Sherman (2001), placodes are localized regions of columnar epithelium that develop from 
the ectoderm in the early stages of embryonic development. Such localized, thickened 
patches of ectoderm give rise to the otic sensory epithelium and other organs of special 
sense (Larsen and Sherman, 2001). Preceding placodal development is the formation of a 
pre-placodal region. This horseshoe-shaped, ectodermal region lies at the border of the 
neural plate (Larsen and Sherman, 2001). As seen in figure 5, placodal precursors are 
located in the common pre-placodal area, which subsequently take on the roles of specific 
placodal progenitors. These differential placodal progenitors are defined by ultimate cell 
fate, gene expression, and other unique properties (Streit, 2008). 
 
Scientists use marker expression to define the multi-stage processes of in vitro 
stem cell differentiation. The stages of placodal development are defined by specific 
transcription factors or genes that become sequentially expressed (Figure 6). Six and Eya 
Figure 5. Pre-placodal 
Precursors Develop into 
Sensory Placodes 
http://mglinets.narod.ru/jpg/oticPlac1.jp
g 
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are transcription factors, known to maintain expression in all developing placodes; 
however, they are lost in the interplacodal domains (Larsen and Sherman, 2001). Later 
specification of placodal regions is defined by the expression of the Pax family of 
proteins. Of particular interest in this study, and otic differentiation studies in other 
laboratories, is transcription factor Pax2. Pax2-positive cells are thought to define otic-
progenitor fate, providing evidence for otic placode identity. Figure 6 shows the 
sequential subdivision of respective placodal territories, as established by Streit (2008).  
 
 
 
e. Step-Wise Otic Specification 
 Recent studies have established systematic approaches to in vitro hair cell 
differentiation with the use of ESCs. Successfully attaining each stage in differentiation 
in a methodical manner is crucial. A homogenous pool of cells derived from each 
characteristic stage is the goal of directed differentiation in hESCs. This idea is at the 
forefront of stem cell science, and the early stages in otic differentiation protocols are 
thought to be critical in yielding the desired results of otic specification. As established 
by Koehler and Hashino (2014), a systematic and multi-staged process of in vitro 
differentiation is the key to mimic the developmental stages of the vertebrate inner ear 
Figure 6. Sequential 
Subdivision of the 
Placodal Territories 
Streit (2008) 
!
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(Figure 7).  The early stages of differentiation begin with division of definitive ectoderm 
(DE) into the non-neural ectoderm (NNE) and neural ectoderm (NE) (Koehler and 
Hashino, 2014). The addition of high BMP tailors cells towards induction of the NNE 
(Koehler and Hashino, 2014). Koehler and Hashino (2014) states that the next stage of 
differentiation involves the formation of the pre-placodal ectoderm (PPE), for which 
BMP signaling must be decreased, while FGF signaling must simultaneously be 
increased. At the next stage, PPE differentiation is directed towards obtaining marker 
expression characteristic of the otic-epibranchial domain (OEPD), as a result of FGF 
application. This is a key step in developing a homogenous pool of otic progenitors that 
may characterize the otic placode-like cells in vitro (Koehler and Hashino, 2014). 
Moreover, differentiation through the later stages, as described by Koehler and Hashino 
(2014), includes factors of Wnt signaling, along with a simultaneous down-regulation of 
FGF signaling. The process is described step-wise in Figure 7 (Koehler and Hashino, 
2014).  
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Koehler and Hashino (2014) has further established that early differentiation can 
be distinguished by the expression of Pax proteins. As stated previously, Pax2 is of 
particular interest because it is shown to be up-regulated in the formation of the otic 
placode (Larsen and Sherman, 2001). A Pax2-positive pool of cells may indicate the 
successful differentiation of otic progenitors. 
 
f. Introduction to Fibroblast Growth Factors 
It has become well established that all major vertebrate groups require Fibroblast 
Growth Factor signaling to initiate the induction of the otic placode (Yang, 2013). 
Fibroblast Growth Factors (FGFs) are multifunctional proteins that have significant roles 
Figure 7. Overview of 
Inner Ear Induction 
Protocol 
Koehler and Hashino, (2014) 
!
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in a wide array of cells and tissues (Ornitz and Itoh, 2001). FGFs largely act as 
modulators of proliferation, differentiation, and cell migration (Orntiz and Itoh, 2001). 
There are four receptor subtypes, classified as receptor tyrosine kinases, which can be 
activated by a variety of the twenty-two members of the FGF family (Ornitz and Itoh, 
2001). Upon ligand-receptor interaction, FGF receptors (FGFRs) induce the activation of 
a variety of intracellular signaling networks and canonical downstream pathways. Such 
cellular phenomena are of interest in a plethora of research fields. 
 
g. FGFs and the Otic Placode 
FGF signaling is a key regulator in the differentiation of the OEPD from the PPE, 
which can be recapitulated using a combination of sequential molecular signals in the in 
vitro hESC system. Several studies have explored and documented the roles of FGFs in 
otic specification in mouse, zebrafish, and chick (Streit, 2008). Such literature provides 
the motivation to optimize the use of FGFs to differentiate hESCs into a homogenous 
pool of otic progenitor-like cells. The identity of FGFs involved in otic induction is 
distinct among different species, as shown in Table 1 (Yang, 2013). Not listed in Table 1 
is FGF2, which has been proven to be a more “promiscuous” molecule of the FGF family 
and is used to activate the FGFRs in a variety in vitro contexts (Ornitz and Itoh, 2001).  
Table 1 
Mice FGF3 and FGF10 
Zebrafish FGF 3 and FGF8 
Chickens FGF3 and FGF19 
 
h. FGFs and their Downstream Signaling 
A meticulously defined network of signaling molecules, inputs, and targets 
provide the balance necessary for maintaining the health and differentiation of pluripotent 
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stem cells. The workings of the major cellular signaling pathways have been elucidated in 
a variety of established studies; however, the relationship between signaling pathways 
downstream of FGF-FGFR ligand-receptor complexes are yet to be determined in the 
context of otic specification. Further study of the canonical downstream pathways, 
including the ways in which they inhibit, positively regulate, or integrate signaling inputs, 
may be a key factor in determining the effects of FGFs on the early stages of otic 
specification. The signaling networks downstream of activated FGFRs are widely known 
to involve the ERK, AKT, and PLCγ pathways (Figure 8). The pathways generally 
mediate distinct processes in the cell – ERK mediates cell proliferation; AKT mediates 
cell survival; PLCγ mediates cell motility (Figure 8).  
 
 
 
 The activation of the ERK pathway, upon FGF-FGFR ligand-receptor interaction, 
has been implicated in the early stages of otic specification (Yang, 2013). In Figure 9, 
Yang (2013) suggests that FGF signaling activates the ERK pathway, which subsequently 
mediates Pax2 otic progenitor marker expression. Figure 9 shows chick embryos, at the 
stage of otic placode specification, treated with inhibitors against FGFR and components 
Figure 8. Overview 
of ERK, AKT, and 
PLCγ Downstream 
Signaling Pathways  
Goetz and Mohammadi 
(2013) 
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of the ERK/MAPK, AKT, and PLCγ pathways (Yang, 2013). Only embryos cultured 
with the FGFR and ERK inhibitors showed a significant decrease in Pax2 expression 
(Figure 9). FGF activation of the ERK pathway may be the key mediating factor that 
promotes Pax2 otic marker expression in cells driven towards obtaining otic placode-like 
character. The results provide motivation to continue the optimization of FGF signaling 
in differentiation protocols geared towards otic placode specification. By efficiently fine-
tuning the canonical downstream pathways of FGF-FGFR signaling, scientists may 
potentially mediate desired otic marker expression.  
 
  
  
Figure 9. ERK Signaling 
Mediates an Increase in Pax2 
Upon FGF Application 
Yang (2013)!
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III. Hypotheses and Aims 
Our long-term goal is to enhance the efficiency of hair cell differentiation from 
hESCs by systematically optimizing small molecules essential for inner ear development. 
The central hypothesis for the current project is that optimization of ERK signaling 
through FGF activity will increase the efficiency of the early stages involved in hair cell 
differentiation. Recent studies provide the motivation to examine the role of FGFs in otic 
placode specification. FGF signaling through activation of canonical downstream 
pathways has not yet been elucidated in the context of otic specification in an in vitro 
human system. Optimizing the use of FGFs and elucidating the roles of downstream 
canonical pathways, ERK, AKT, and PLCγ, may prove to be key factors in guiding the 
early stages of otic induction and, subsequently, the formation of a homogenous pool of 
otic progenitor-like cells. The stages of particular interest in this study are shown in 
Figure 1, which represent the step-wise differentiation stages geared towards mimicking 
development of the otic placode. The Figure 2 paradigm represents our plans to apply 
FGFs to a group of specified PPE-like cells derived from hESCs in a context that guides 
them towards otic placode specification. 
 
 
 
 
 
hESCs! DE! NNE! PPE! OEPD!
Figure 1. Focus on the Early Stages of Otic Specification 
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To our knowledge, these are the first attempts made in devising a protocol to 
optimize the use of FGFs on PPE-specific cells, to efficiently drive differentiation of the 
otic placode. The Validation Protocol Assays detailed below serve as a means by which 
we can determine that a biological effect results in canonical downstream pathway 
activation, upon FGF application to H7 EBs. The Validation Protocol Assays allow us to 
determine the experimental conditions that can be translated to the Contextual Culture 
Paradigm, aimed at specifically differentiating PPE-like cells into cells characteristic of 
the OEPD, and subsequently, the otic placode.  
 
  
Figure 2. Applying FGFs after Formation of PPE Should Induce OEPD and 
Subsequently Otic Progenitors 
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IV. Generation of Embryoid Bodies Using Micro-patterned Silicone 
Substrates 
 
a. Introduction 
Embryoid bodies (EBs) are multicellular stem cell aggregates, which closely 
mimic the earliest stages of embryonic development. EBs are thus used as the integral 
catalyzing event in most stem cell differentiation protocols. The three-dimensional 
aggregates play crucial roles in the step-wise in vitro differentiation of hESCs into a 
variety of cell fates. While there are several methods for inducing the formation of EBs 
from ES cells (Table 1), forced aggregation is the most advantageous. Forced aggregation 
of EBs is a high throughput method that enhances reproducibility and strong control over 
EB size. AggreWellTM is a well-known, commercially produced option for using forced 
aggregation as a standardized approach to produce EBs. AggreWellTM plates contain well 
inserts that have micro-well depressions patterned in the top surface. Cells may be spun 
into the micro-wells, by which they are forced to come together and form aggregates, or 
EBs, which are fed various molecules in adherence to the specific differentiation protocol 
under study. AggreWellTM plates are highly efficient; the AggreWellTM800 insert yields 
300 EBs, and an AggreWellTM400 insert yields 1200 EBs. With only 8 inserts per 
AggreWellTM plate, this method for forced aggregation is unfortunately expensive and 
prohibits the use of this high throughput method for many stem cell laboratories.  
 
 
 
 
 
 
! 18!
 
 
By using affordable materials, the AggreWellTM plates were duplicated (inspired 
by Dahlmann, 2013). This simple replication method involved removing the patterned 
24-well size insert from the commercial AggreWellTM plates and duplicating it with 
another material – Sylgard 184. These duplicated inserts are similar to the original 
inserts; they are Polydimethylsiloxane (PDMS)-based, non-porous, non-toxic, and 
optically clear to facilitate visualization of EB formation and simultaneous imaging 
studies. Additionally, the duplicated Sylgard inserts were coated with materials 
[Polyethylene glycol (PEG) or Polyhydroxyethylmethacrylate (pHEMA)] to inhibit 
adhesion of cells to the PDMS surface, in order to more efficiently promote aggregation 
of stem cells into EBs.  
 
b. Substrate Materials do not Impact EB Morphology 
Random fields of EBs were imaged and used for quantitative analysis on ImageJ 
Software (Figure 1a). By carefully tracing the EB shape on the software (Figure 1b), 
measures of Area, Circularity, and Aspect Ratio were calculated. EBs made on any of the 
four different plates (AggreWellTM, PEG-coated, pHEMA-coated, Sylgard-uncoated) 
Table 1. Methods of Forming EBs 
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consistently fell into a bimodal size distribution. The two classified groups of EBs were 
based on area and separated at the 9000 µm2 mark (Figure 2a). Statistical tests were run 
on these two groups separately. EBs larger than 9000 µm2 differed among the four 
experimental groups in circularity and aspect ratio (the proportional relationship between 
the EB’s width and height) by single factor ANOVA (p<0.05, n=3) (Figure 2b). Tukey 
post-hoc comparisons showed that EBs formed on uncoated Sylgard inserts were 
statistically more circular than those formed on AggreWell inserts (*p<0.05). Overall, the 
EBs formed on the duplicated Sylgard inserts, whether coated or uncoated, closely 
compared to the size and shape of EBs formed on the commercial AggreWellTM inserts 
(Figure 2b).  
 
 
 
a. 
Figure 1. EB Morphology 
1a: Random field of EBs. 1b: EBs were traced with ImageJ Software. 
 
b. 
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Figure 2. Quantification of EB Morphology 
2a: EBs consistently fell in a bimodal size distribution. 2b: The two groups of EBs 
are cut off at 9000 um2; statistical analysis of Area, Circularity, and Aspect Ratio 
is calculated separately for the two groups.  
 
a. 
b. 
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c. Substrate Materials do not Impact Lineage Choice 
The three lineage markers for mesoderm, ectoderm, and endoderm were studied 
by staining the EBs with Brachyury, Nestin, and Gata6, respectively (Figure 3). We 
sought to confirm that the Sylgard 184 and/or coating materials did not impact lineage 
acquisition. This result was quantified by measuring the fluorescence signal from gray 
scale images, by tracing the borders of stained regions with ImageJ Software. The 
substrate variable groups were compared by ANOVA, which concluded that none of the 
four tested inserts influenced the EBs to drive towards a specific lineage during 
development, as determined by lineage marker staining (p>0.05, n=1). 
  
 
 
 
 
Figure 3. Staining of three lineage markers – Brachyury (mesoderm), Gata6 
(endoderm), Nestin (ectoderm) 
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The ANOVA results for substrate variable groups were supported by qPCR data 
shown in Figure 4a. Results showed no significant differences in lineage marker 
expression between the four groups. qPCR was also used to study Pax2 otic progenitor 
marker expression of EBs formed on the four variable substrates. Results revealed a 
slightly lower Pax2 expression in EBs derived from PEG- and pHEMA-coated inserts as 
compared to EBs derived from AggreWellTM inserts (n=1) (Figure 4b). Since Pax2 is an 
otic marker that we seek to up-regulate in our step-wise differentiation protocols, it was 
most promising to move forward in producing EBs with the use of AggreWellTM and 
Sylgard 184 inserts. 
 
d. Discussion 
Our work provides that duplicating AggreWellTM inserts with other substrate 
materials neither affects neither morphology nor lineage choice. This method of 
AggreWellTM insert replication, with the use of affordable materials, proves to enhance 
the feasibility of embryoid body formation. In this way, EBs are more easily aggregated 
Figure 4. Quantification of Potential Lineage Biases 
4a: Quantification of Lineage Marker Staining. 4b: Pax2 Expression Relative to 
AggreWellTM 
 
b. a. 
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for use as the initial catalyzing event in differentiation strategies. Additionally, cost and 
efficiency are greatly improved, providing an attainable and potentially widespread 
benefit in regenerative medicine, drug discovery, and basic science research. While EBs 
produced on all inserts showed a bimodal distribution of sizes, this observation may be 
eliminated with use of filtration by cell straining or by the addition of molecules proposed 
to induce factors of differentiation.  
A key observation from our results indicates that there was a slightly lower Pax2 
expression in EBs derived from PEG- and pHEMA-coated inserts, as compared to EBs 
derived from AggreWellTM inserts. This suggests that substrate material may affect the 
expression of placodal markers in sequential cell differentiation. As we aim to optimize 
the step-wise differentiation of hESCs into otic progenitor-like, Pax2-positive cells, our 
subsequent protocols steer away from the use of duplicated PEG- and pHEMA-coated 
inserts. All subsequent work in this study incorporates the use of duplicated, uncoated 
Sylgard-184 or commercial AggreWellTM inserts instead. 
 
This work was presented at the 37th Annual Midwinter Meeting of the Association for 
Research in Otolaryngology, 2014.   
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V. The Validation of FGF Assays 
a. Introduction 
The optimal use of FGFs in human stem cell protocol has not yet been explored. 
The application of FGFs in ill-defined doses or concentrations could lead to the activation 
of a plethora of downstream pathways, which may be self-defeating and self-limiting in 
the success of a differentiation protocol. In this study, maximizing activation of ERK 
upon FGF application is a primary objective, since ERK has been directly implicated in 
otic induction (Yang, 2013). Identifying the dosage, duration of application, and type of 
FGF molecule most effective in activating the ERK pathway may be the key to improved 
otic differentiation efficiency. With the use of the Validation Protocol, we began by 
confirming that application of FGFs on the H7 EBs resulted in a detectable biological 
effect. This justified moving forward with FGF application in an otic induction protocol 
with respect to the determined dosage, duration of treatment, and FGF type.  
 
b. The Validation Protocol Experimental Design 
Embryoid bodies (EBs) are formed by forced aggregation, cultured in suspension, and 
tailored towards ectodermal lineage by inhibiting TGF-β signaling (with TGF-β inhibitor 
SB431542) in 3D culture. At 48 hours of EB formation, FGFs are applied for a particular 
duration of time. According to literature, the ERK, AKT, and PLCγ pathways should be 
activated within 1 hour of FGF application, so this was tested under our experimental 
conditions. Activation of these three downstream canonical pathways was subsequently 
assayed by Western blotting. This design of the Validation Protocol is summarized in 
Figure 1 below. In most cases, the experiments below were single experiments and were 
not repeated for statistical analysis, since the primary goal was to asses (1) expression of 
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receptors, (2) response to FGF dose, (3) response to FGF type, and (4) detectability of 
phospho-ERK, -AKT, and -PLCγ, in hESCs, and other positive controls as needed. The 
Validation Protocol serves as an affirmation that FGF application on the H7 EBs results 
in a biological phenomenon that can be further optimized.  
 
 
 
c. The Validation Protocol Results  
i. FGFR1-4 Present in H7 hESCs and H7 EBs  
Routine PCR was performed to confirm the presence of the FGFR’s in the H7 
EBs and hESCs. Figure 2 depicts that all four receptor subtypes were present in both 
groups, as expected. This provided the motivation to move forward with the Validation 
Protocol and apply FGFs to the H7 EBs. 
Figure 1. Validation Protocol Experimental Design 
 EB!Formation:!Plate!H7!cells!as!single!cells!in!KOSR!Medium!+!Y27632!+!SB431542!
24!hours!of!EB!Formation!
48!hours!of!EB!Formation:!FGF!Treatments!
Western!blotting!assay!for!activation!of!downstream!signaling!pathways!–!ERK,!AKT,!and!PLCγ!!
Day$0 
Day$1 
Day$2 
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ii. ERK Downstream Signaling is activated within 1 Hour of FGF Treatment 
In establishing a protocol for targeted downstream activation, the duration of FGF 
treatment is a key variable. As established in prior literature, phosphorylation events 
occur within 1 hour of FGFR signaling. A high dose of FGF3/10 (100 ng/mL) was 
applied to EBs (dosage inspired by Yang, 2013 and Chen et. al., 2012), in order to 
confirm the phosphorylation of ERK (Figure 3).  
Figure 2. Routine PCR for 
Detection of FGFR1-4 
Intron-spanning PCR 
primer-pairs were designed 
against FGF Receptors 1-4. 
Expected bands: 294 bp 
(FGFR1), 363 bp (FGFR2), 
276 bp (FGFR3), and 393 
BP (FGFR4).  
2a: 500 ms exposure; H7 
hESC samples are lanes 2-5; 
H7 EB samples are lanes 6-
9. Note: The expected band 
for FGFR3 is present, but 
faint. There is an additional, 
larger band of unknown 
origin also present in the 
FGFR3 lane. 
2b: 500 ms exposure; no-
template control.  
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As shown in Figure 3, we confirmed the activation of the downstream ERK 
pathway for the 30-minute and 60-minute drug treatments by detecting the 
phosphorylated protein form. Levels of pERK and tERK bands were measured via 
densitometry in ImageJ and normalized to actin-loading control. The ratio of normalized 
pERK/tERK, as compared to the media-controls, showed a 6- and 7-fold increase in the 
30- and 60-minute samples, respectively (see Methods). Nonspecific bands were 
routinely seen at the ~58 kD mark for Western blots performed in our study. Several 
approaches were tested to identify the band’s reason for routine presence, but detection of 
the ~58 kD band in Western blots was unsuccessfully attenuated. It was deduced that this 
band was present so often due to nonspecific binding of the secondary antibodies.  
 
iii. No Effect of BSA and HS in Downstream Phosphorylation of ERK 
The FGF drug treatments were made with Bovine Serum Albumin (BSA) (see 
Protocols), a known stabilizing factor for FGFs, as well as many other proteins, in 
solution. We sought to confirm that the activation of downstream ERK signaling (Figure 
Figure 3. 30 Minute vs. 60 Minute Duration of FGF3/10 Treatment 
High dose of FGF3/10 (100 ng/mL) was applied to cells for 30-minutes and 60-
minutes. Treatments were compared to media-only controls. Arrows show 
expected bands. Unmarked bands are the result of nonspecific binding. 
30$Minute! 60$Minute!
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3) was the result of FGF application, rather than the result of BSA in the drug 
preparations, since BSA is known to interact with numerous molecules and proteins to 
influence the growth of cells in culture (Francis, 2010). Adding BSA to the media-control 
tested this effect; it was anticipated that, if the BSA indeed influenced growth of cells 
through downstream signaling, phosphorylated ERK would be present in samples treated 
with Media+BSA.  
Additionally a large body of evidence has established the direct role of Heparin 
Sulfate (HS) as a stabilizing factor in the formation of an active FGF-FGFR ligand-
receptor signaling complex (Ornitz and Itoh, 2001). HS was either added or omitted from 
the drug treatment; it was anticipated that HS+FGF3/10 would show an increase in ERK 
phosphorylation due to the stabilizing effect on FGF-FGFR signaling complex. The 
effects of BSA and HS on FGF stability and downstream activation are shown in Figure 
4.  
 
The addition of BSA to the media-only control did not enhance phosphorylation 
of ERK, and it did not cause a change in the amount of total ERK protein in the cell. 
Adding BSA to the FGF drug treatments likely did not cause the phosphorylation of ERK 
seen in Figure 3, and BSA was concluded to be stabilizing FGFs, rather than contributing 
Figure 4. Effects of BSA 
Heparin Sulfate on FGF 
Stability and Downstream 
activation 
FGF3/10 was applied at 100 
ng/mL for 1 hour, all compared to 
a media only control.  
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to cell growth through downstream signaling pathways. Because we saw no effect in the 
media-control, we decided that it was unnecessary to include BSA in the media for 
subsequent experiments.  
The addition of FGF3/10 causes a slight increase in phosphorylation; however, no 
major difference in phosphorylation is detected with the addition of HS (FGF3/10+HS 
sample). Both FGF3/10-treated samples (with or without HS) show normalized 
pERK/tERK fold-changes of less than 2, relative to the media-only control. Due to no 
visible and calculated effects, HS was omitted from subsequent FGF drug treatments. 
 
iv. FGF3/10 Dosage Response 
FGF dosage is another key variable to be elucidated in analyzing downstream 
signaling upon FGF application. An optimized FGF dosage, directed towards mediating 
ERK phosphorylation, has not been previously tested in otic specification protocols. As 
stated previously, 100 ng/mL of FGFs may be considered a “high” dose according to 
related literature (Yang, 2013 and Chen et. al., 2012). Thus, we tested additional FGF 
concentrations at 10-fold lower and 10-fold higher (Figure 5). 
 
It was expected that ERK phosphorylation would increase proportionally to the 
applied FGF3/10 dosage; however this was not observed. A basal level of 
Figure 5. FGF3/10!Dosage!
Response 
FGF3/10 was applied at 10, 100, 
1000 ng/mL for 1 hour, compared 
to a media-only control.   
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phosphorylation was detected in the media-control, and this band was not significantly 
changed upon the addition of 10 or 100 ng/mL FGF3/10. While there may have been a 
basal level of endogenous FGFs that contributed to ERK activation in Figure 3, additional 
FGF3/10 seemed to cause an increased effect, though only slightly. The fold-change in 
normalized pERK/tERK is less than 2, compared to media-only controls, for both 10 and 
100 ng/mL FGF2-treated samples.  
The 100 ng/mL FGF3/10-treated sample condition was a replication of the high 
FGF3/10, 1 hour treatment condition seen in Figure 3; phosphorylation was unexpectedly 
not as robust as seen previously (Figure 3). There are many possibilities for this resulting 
difference (see Discussion and Future Directions). However, since the 1000 ng/mL 
condition showed a clear increase in ERK phosphorylation (5-fold change relative to 
media-only control), we concluded that the FGF activity does increase with dose and 
were confident that the pERK effect is due to added FGF. Following Yang (2013) and 
Chen et al., (2012), the high dose in subsequent experiments was set to 100 ng/mL, but 
even higher doses might be considered in the future (see Discussion).  
 
v. FGF2 vs. FGF3/10 Response 
FGF2 is considered a more promiscuous growth factor, with many recognized 
receptor and ligand interactions. Since all FGFRs were identified in H7 hESCs/EBs, we 
thought it was possible that FGF2 would induce more robust phosphorylation of 
downstream targets. The FGF2 effect on EBs was explored. 
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Results in Figure 6 indicate that FGF2 treatment activated the ERK pathway. By 
comparison, the effects seen with FGF3/10 were absent or very faint. Normalized 
pERK/tERK showed a 36-fold increase in phosphorylation, relative to the media-only 
control. The FGF3/10 treated sample conditions were identical to those in Figures 3, 4, 
and 5. Of those experiments, only the experiment in Figure 3 resulted in visible ERK 
phosphorylation upon FGF3/10 drug treatment. The differences in FGF3/10 activity over-
time could reflect biological changes in the cells upon repeated passaging, inherent 
variance in cell cultures, or effects at the detection limits of our system (See Discussion 
and Future Directions). Since FGF2 effects were more robust, subsequent experiments 
were conducted with high dosages of this growth factor ligand.  
 
 
 
 
 
Figure 6. FGF!2!vs.!FGF!3/10 
Samples were treated with a media-
only control, high FGF2, or high 
FGF3/10 for 1 hour. Note: FGF3/10 
sample was depleted before reaching 
the final lane intended for total ERK 
analysis. 
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vi. Assay for Canonical Downstream Signaling – ERK, AKT, PLCγ Pathways 
Thus far, the Validation Protocol Assays affirmed that biological activity was induced 
when H7 EBs were treated with FGFs. Because of stronger pERK detection with FGF2, 
this molecule was added to the EBs to test for the activation of parallel pathways AKT 
and PLCγ. An FGF treatment duration-response assay confirmed the activation of 
downstream signaling with just 5 minutes of FGF drug treatment (data not shown); thus, 
5- and 30-minute durations of FGF2 treatment were used in the following experiment.  
 
At both durations, ERK and PLCγ showed activation upon FGF2 application. A 
15- and 25-fold increase in ERK phosphorylation was seen in the FGF2 5- and 30-min 
samples, respectively. A 7- and 10-fold increase in PLCγ phosphorylation was seen in the 
FGF2 5- and 30-min samples, respectively. Neither visible nor quantifiable increase in 
phosphorylation was seen on the AKT blots (expected detection at 60kD). The ~58 kD 
nonspecific band discussed above could have masked AKT activation, or there may have 
been a lack of activation altogether (see Discussion and Future Directions). The reasons 
for which FGF2 showed more effective downstream activation than FGF3/10 are 
Figure 7. FGF3/10!Dosage!Response 
FGF2 was applied at high dose for either 5- or 30-min, and compared to media-
controls (5- and 30-min). Note: As described in Figure 1, all blots included a 
nonspecific band at ~58 kD (not shown). 
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discussed below (see Discussion and Future Directions). Repetition of this experiment, 
for pAKT Western blotting in the H7 EBs, is necessary.  
 
vii. PDGF-Treated NIH3T3 Cells Show AKT Activation  
We sought to confirm that the pAKT and tAKT antibodies worked under our 
experimental and laboratory conditions, due to the lack of detectable results seen in 
Figure 7. PDGF-treated NIH3T3 cells were used as a positive control, since this 
biological activity is known to have reproducible effects on downstream activation of 
AKT (Zhang, 2014). NIH3T3 mouse embryonic fibroblast cells were provided by the 
Schacht Laboratory (University of Michigan Medical School, Department of 
Otolaryngology).  
 
Results in Figure 8 confirmed that phosphorylated and total antibodies against 
AKT do indeed show specific binding. The ~58 kD nonspecific band seen in EB 
experiments was absent in the NIH3T3 samples. All bands were normalized to actin. 
Normalized pAKT/tAKT shows a 30-fold increase in phosphorylation of both PDGF-
Figure 8. PDGF$Treated!
NIH3T3!Cells! 
PDGF was applied at either 
25 or 50 ng/mL. Note: ~58 
kD nonspecific bands are 
absent.  
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treatment concentrations, relative to the media-only control. Similarly, ERK shows a 45-
fold and 30-fold increase in phosphorylation, in the 25 ng/mL and 50 ng/mL PDGF-
treated samples, respectively. These results suggest that the antibodies were working well 
in our hands. The ~58 kD nonspecific band could have masked AKT detection in the 
Figure 7 experiment.  
It is also possible that there are distinct biological phenomena occurring in the H7 
EBs, which prohibited the effects of FGF treatment on canonical downstream AKT 
signaling. The hESCs may have reduced abundance of the relevant AKT enzyme or 
direct upstream/downstream effectors. Additionally, phosphorylation could be occurring 
at Serine or Threonine residues that are undetectable with our pAKT antibody. The 
experiment in Figure 7 must be repeated, in order to confirm the absence or presence of 
effect on phosphorylated and total AKT, in conjunction with methods to clean up the ~58 
kD nonspecific signal to prohibit masking. 
 
d. Discussion and Future Directions 
The Validation Protocol was used to confirm the biological effect of FGFs on the 
H7 hESCs. The primary goal was to assess (1) expression of receptors, (2) response to 
FGF dose, (3) response to FGF type, and (4) detectability of phospho-ERK, -AKT, and -
PLCγ in hESCs and other positive controls as needed. Once optimized, these measures 
can be confidently translated to an otic differentiation protocol. The use of FGFs in a 
human in vitro system has not been systematically explored. Thus, our work serves as the 
first attempts, based on prior literature, to optimize FGF use in a hESC in vitro system, 
by targeting the downstream ERK pathway.  
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Previous studies have shown that FGF3 and FGF10 are necessary for otic vesicle 
formation in mouse (Freter, 2008). In Figure 2, there was an effect of high FGF3/10 on 
the downstream activation of ERK in EBs treated with small molecules that should direct 
cells toward obtaining NNE character. However, this effect was not consistent in further 
experimentation (Figures 4, 5 and 6), and instead, FGF2 showed a more robust 
phosphorylation of the downstream ERK target. This could be due to the fact that time 
and passaging of the H7 cells may have changed biological properties, including the 
hESCs’ affinity for FGF3/10. Receptor-ligand interactions may have come to favor a 
more “promiscuous” FGF family member, such as FGF2. Additionally, differentiating 
cells are dynamically changing in terms of fate, and this may reflect changes in the 
relative amounts of FGFR subtypes being translated and effectively translocated to the 
plasma membrane.  
A further step in elucidating the activity of FGF ligand subtypes would be to 
perform routine PCR on the H7 cells and confirm that the same receptors are still present 
over time, as in Figure 1. Additionally, Western blotting for the FGFR1-4 may be used to 
confirm that protein is being translated and immunohistochemistry could confirm surface 
expression. Certain FGFRs have higher affinity for specific FGF ligands, and in 
determining which receptors are present and translated in the cells, as well in which 
relative amounts, a relationship may be determined for the affinity of FGF2 vs. FGF3/10 
in the H7 hESCs/EBs. 
Based on previous studies, a high dose of FGFs (100 ng/mL) should be sufficient 
in inducing an effect on canonical downstream pathways (Chen et al. 2012, and Yang, 
2013). As the dosage-response experiment in Figure 5 indicates, downstream 
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phosphorylation of ERK was dose-dependent but was not proportional to the FGF dosage 
applied. The effective dose range and the dose that should cause a maximum ERK 
response have not yet been established in otic differentiation literature. A high dose may 
consist of a concentration that is 10-fold, 100-fold, or even 1000-fold to basal FGF levels 
in the H7 hESCs. This is an opportunity for future experimentation, in which several 
doses can be applied and tested to elucidate which maximizes activation of ERK. Dose-
response experiments were not pursued further in our Validation Protocol Assays because 
relevance to a full otic induction protocol is uncertain. However, the variance in response 
across repeated cultures and the observation of dose-dependent effects underscores the 
need for systematically investigating FGF dose effects in an established otic induction 
protocol.   
An interesting future step may include the study of marker expression patterns in 
the EB stages, both preceding FGF treatment and several days after. It is possible that the 
H7 EBs express markers indicative of other fates, before the addition of FGFs. This may 
drive the response of FGF treatment in an already-fated direction. Following a particular 
lineage can influence the cells to respond to FGFs differentially, in relevance to ERK 
activation and/or lineage marker expression. By learning the expression patterns of 
markers preceding FGF treatment, we may be able to learn whether lineage influence 
induces a mediated response by FGF treatment that is implicated in downstream ERK 
signaling. The subsequent marker expression post-FGF treatment may show an 
interesting directionality of the FGF driven process, potentially through downstream 
ERK activation. Based on our results, we have validated the tools necessary to elucidate 
! 37!
the effects of FGF application on targeted downstream activation in appropriate otic 
protocols.  
! 38!
VI. Contextual Culture Paradigm 
 
a. Introduction 
The validation assays confirmed the activation of ERK in the 3D embryoid body 
culture. ERK activation is a crucial biological effect, thought to mediate the expression of 
Pax2 in differentiating cells, as they adopt otic progenitor character (Yang, 2013). It is 
important to translate the experimental conditions confirmed by the Validation Protocol 
into a context that recapitulates otic induction from pre-placodal ectoderm. The 
Validation Protocol Assays gave us the confidence that a 5-minute duration of FGF2 
treatment (100 ng/mL) should cause a detectable biological effect on canonical 
downstream pathways in a context that is specifically tailored towards forming otic 
progenitors.  
Pre-placodal ectoderm cells can be identified by the expression of 3 
transcriptional regulators – Six1, Eya1, and Eya2 (Leung, 2013). According to Leung 
(2013), these PPE-characteristic markers are both necessary and sufficient for PPE 
specification. The Leung (2013) protocol has provided a means by which pre-placodal 
induction may be reproduced. As seen in Figure 7 of Introduction and Background (Ie), a 
decrease in BMP signaling, along with simultaneous increase of FGF signaling is known 
to be important for PPE specification (Koehler and Hashino, 2014). The Leung (2013) 
protocol for PPE induction focuses on optimizing BMP signaling. The resulting cells 
show expression of PPE marker proteins, including Six1 (Leung, 2013).  
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b. Contextual Culture Paradigm Experimental Design 
The results from Leung (2013) inspired a fellow laboratory member to formulate 
a similar otic differentiation protocol optimized for our H7 stem cell line. This allows her 
to direct hESCs toward a Six1-positive PPE fate, and she has successfully obtained 
reproducible results. Following this Leung (2013)-inspired Contextual Culture Paradigm 
for PPE specification (see Appendix D for stepwise protocol), we sought to fine-tune the 
subsequent formation of the OEPD from the Six1-positive PPE, with the use of our 
validated experimental conditions for FGF treatment of hESCs (see Validation of FGF 
assays). Figure 1 outlines the experimental design of the Contextual Culture Paradigm. 
 
 
 
 
Figure 1. The Contextual Culture Paradigm – Experimental Design 
 Seed!hESCs!on!MatrigelYcoated!plates!with!mTeSR!+!Y27632!
Change!to!Leung!et.!al.!2013!Medium!
Change!medium!every!other!day!
FGF!drug!treatments!and!Western!blotting!assay!for!activation!of!downstream!signaling!pathways!–!ERK,!AKT,!and!PLCγ!!
Day$Y1 
Day$0 
Day$2Y8 
Day$8 
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c. Contextual Culture Paradigm Results 
i. FGFR1-4 Present in Contextual Culture-treated H7 hESCs  
Routine PCR was performed to confirm the presence of the FGFRs in the H7 Contextual 
Culture Paradigm media-treated samples. Figure 1 shows that all four receptors were 
present in the cells as expected. This provided the motivation to move forward with the 
Contextual Culture Paradigm. 
 
Figure 2. Intron-spanning PCR primer-pairs were designed against FGF Receptors 
1-4. Expected bands: 294 bp (FGFR1), 363 bp (FGFR2), 276 bp (FGFR3), and 
393 BP (FGFR4). 1a: 400 ms exposure; H7 hESC samples (positive control) 1b: 
400 ms exposure; Contextual Culture Paradigm media-treated H7 hESCs (lanes 2-
5) and no-template control (lanes 6-9). Note: FGFR3 is present, but faint. There is 
an additional, larger band of unknown origin also present in the FGFR3 lane. 
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ii. No Effect Seen in Downstream Signaling 
An initial experiment focused on 5-minute application of high-dose FGF2, but no 
reliable increase in downstream FGF signaling was observed. Thus the experiment was 
repeated with 30- and 60-minute FGF2 durations (Figure 3), with the anticipation that an 
increase in treatment duration may reveal reliable effects. Figure 3 is representative of 
both trials 5-minute trials.  
 
 
In both trials, the blots showed nonspecific binding and large amounts of 
background signal in each lane. This greatly complicated quantification and calculation. 
It is possible that a basal level of phosphorylated ERK was present in the cultures and 
went unseen due to the large amounts of background and nonspecific binding (Figure 3a); 
however, there was no change in phosphorylation when comparing media-controls and 
a.! b.!
c.!
Figure 3. No Effect Seen in Downstream Pathways – ERK, AKT, PLCγ. 
3a: ERK blots. 3b: AKT blots. 3c: PLCγ blots. Note: ~58 kD nonspecific band 
seen on all blots.  
 
! 42!
FGF2-treated samples. Because all Contextual Culture Paradigm-treated samples showed 
the ~58 kD band for each antibody that was used in Western blotting, it was unclear 
whether the bands shown in Figure 3b were representative of AKT protein (expected at 
~60 kD) (Figure 3b). It is quite possible that there was a basal level of AKT 
phosphorylation present in the hESCs, masked by nonspecific binding, or that there was 
no signal at all (see Discussion). Contrastingly, PLCγ showed a slightly darker band of 
the phosphorylated form in the 30- and 60 minute-treated samples (Figure 3c). The 30- 
and 60-minute FGF2-treated samples both show less than a 3-fold change in normalized 
pPLCγ/tPLCγ, relative to the respective media-controls. This study must be repeated 
under similar conditions, with attempts to clean up the signal and produce quantifiable 
results. Nonetheless, the absence of reliable pERK signaling raises important concerns 
about the ability of FGFs to influence the PPE-like cells to adopt an otic progenitor-like 
fate. 
 
iii. FGFR 1 and 4 are Present in Treated and Untreated hESCs 
Since we confirmed the presence of receptor RNA in the treated and untreated 
cells (Figure 2), we further sought to confirm that the receptors were being translated to 
protein. FGF3 and FGF10 are known to activate FGFR1b, and FGF2 is known to activate 
FGFR1a, 1b, 2a, 3a, and 4 (Ornitz et. al, 1996). Additionally, FGFR1 and FGF4 have 
sequence dissimilarities, but their C-terminal domains mediate similar functions in 
forming a comparable three-dimensional tertiary protein structures (Sørensen, 2006).  
Such information, and FGFR1/FGFR4 presence in the hESCs and Contextual Culture-
treated cells, provided reason to test for detection of the two receptor proteins by Western 
blotting. Figure 4 shows the results of this experiment.  
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Western blotting confirmed the presence of FGFR1 and FGFR4 protein in the 
cells. No difference between the control and treated hESCs was detected. Repetition of 
the experiment in Figure 3 is necessary, but due to strong detection of both receptors we 
presumed that repeated trials would not provide different results (see Discussion).   
 
d. Discussion 
Our penultimate goal is to maximize differentiation of otic progenitors by 
optimizing the downstream signaling pathways, particularly ERK, activated upon FGF 
treatment of hESCs. The pilot results from the Contextual Culture Paradigm study 
suggest that FGFRs were present in the hESC-derived PPE, based on PCR and Western 
blot data (Figure 1 and 4); however, activation of the downstream canonical pathways 
was not detected (Figure 3). The experiment shown in Figure 3 is representative of results 
from two independent, 5-minute FGF2-treatment experiments, but further repetition, 
possibly with greater input material, is necessary before modifying this basic approach. 
Figure 4. FGFR 1 and 4 
Proteins are Present. 
FGFR1 and FGF4 show 
doublets, as expected. 
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Several possibilities may reconcile the positive effects seen in EBs and lack of detectible 
effects seen in the PPE protocol. These possibilities are considered in detail below.  
The chronological time-line for step-wise otic differentiation, as defined by 
Koehler and Hashino (2014), establishes that FGFs are necessary early in differentiation, 
before formation of the PPE (Figure 7 of Introduction and Background, Ie). In our 
Contextual Culture Paradigm, FGFs are added after the formation of the PPE; this time-
course may be unfavorable for downstream activation. At this delayed time-point, there 
may already be a basal level of endogenous FGFs present. Endogenous FGF ligands may 
be saturating the FGFRs present on the cell membranes. This could explain the slight 
phosphorylation of PLCγ, under all media-control and culture-treated conditions seen in 
Figure 3. 
The FGF-FGFR ligand-receptor interaction complex may not be stable in the PPE 
culture. The Heparin Sulfate concentration, included in the FGF drug treatment media, 
may have been too low. Perhaps basal concentrations of HS were not adequate in 
promoting ligand-receptor stability. Instability of the interaction complex may mediate 
only a transient interaction between the ligand and receptor; such transient interaction 
may be inefficient in promoting downstream signaling events, such as dimerization of the 
receptor tyrosine kinases, trans-auto-phosphorylation of the intracellular tails, and thus, 
activation of intrinsic protein kinase activity (Alberts, 2008). This could lead to the 
absence of docking sites necessary for the proteins involved in downstream signal 
transduction.  
It is possible that phosphatases are highly localized near the FGF-FGFR ligand-
receptor signaling complexes. They may quickly dephosphorylate the trans-auto-
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phosphorylation activities of the dimerized receptor tyrosine kinases. In this way, 
intrinsic protein kinases would be unable to potentiate downstream effects, due to the 
quick deactivation by phosphatases.  
The Contextual Culture-treated hESCs may not express the appropriate density of 
FGFRs on the plasma membrane. There are several possible reasons for such cellular 
behavior. FGFRs in the PPE cultures may require longer or stronger exposure to FGFs, 
which may facilitate the translocation of additional FGFRs to the plasma membrane. 
Alternatively, vesicle-mediated transport from the trans-Golgi network to the plasma 
membrane may face a potential roadblock that impedes translocation of FGFRs (Alberts, 
2008). Furthermore, additional proteins, such as the SRC family members, are known to 
be necessary in promoting localization of FGFRs to the plasma membrane (Liu, 1999). 
The mere addition of FGF proteins alone may not adequately induce localization of 
FGFRs on the plasma membrane. It is also possible that the FGFRs are undergoing 
receptor-mediated endocytosis upon ligand binding. According to Sørensen (2006), FGFs 
that bind FGFR1 and/or FGFR4 may undergo endocytosis upon receptor-ligand 
interaction at the plasma membrane. The complexes may be retrogradely transported to 
the cytosol and nucleus, where FGF family members play a role in transcriptional 
activation (Sørensen, 2006).  
Additionally, differentiating cells are dynamically changing in terms of fate, 
proliferation, adhesion, and migration (Perrimon, 2012). The unique signals and 
interactions between pathways, as well as the integration of transcription factor effectors, 
promoters, and inhibitors, are subject to change. Such a network of cellular phenomena 
may direct cells towards specific fates (Perrimon, 2012). It is possible that the PPE-like 
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hESCs may have obtained predetermined fates susceptible to a culmination of FGF 
antagonists, or downstream feedback inhibitors that could impact FGF signaling and 
canonical downstream activation.  
Since hESC differentiation leads to considerable heterogeneity, the lack of a 
detectable signal could result from poor signal detection in a limited pool of cells or 
inhibitory activity from competing and/or parallel pathways. The PPE-induction protocol 
is expected to generate only 70% Six1-positive cells (Leung, 2013). An even smaller 
subset is expected to exhibit multiple PPE markers. Therefore, the applied FGFs may be 
operating on a relatively small pool of FGF-competent cells, making it difficult to 
ascertain downstream activation with whole-cell lysates.  
In addition to the intrinsic cell properties that may have contributed to the results, 
factors in our approach may need to be further optimized. Dosage, duration, and FGF 
type were explored in the Validation Protocol Assays; however contextual differences 
may render hESCs and PPE differentially susceptible to the two treatments. Experimental 
conditions may not be simply translatable from the Validation Protocol to the Contextual 
Culture Paradigm. Future experimentation in the context of otic induction must be 
pursued to explore different dosage, duration and FGF types involved in the Contextual 
Culture Paradigm. 
 
e. Future Directions 
Further studies will be necessary to evaluate the competence of our Contextual 
PPE cells to be influenced by FGFs. As noted in the Discussion, the lack of response 
could be intrinsic to the cells (excessive endogenous FGF, insufficient endogenous HS, 
de-phosphorylation of RTKs by highly localized phosphatases, poor surface expression 
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of FGFRs, and predetermined fates) or could reflect problems with our approach (signal 
detection, dose, duration, FGF type, and timing). Discussed below are potential future 
studies that may elucidate these possibilities.  
A basal level of endogenous FGFs present in the hESCs may be inhibiting any 
additional up-regulation by FGF-FGFR binding and signaling. Using an FGFR inhibitor 
could confirm that this is the case, if activation of ERK were blocked even after addition 
of FGF. By this rationale, downstream signaling targets and other immediate 
transcriptional targets, would show decreased phosphorylation and signal detection, 
respectively. Inhibitors may include (1) the use of antibodies directed against an antigen 
common to all four FGFR receptor subtypes, (2) the use of siRNA complementary to 
FGFR, or (3) the use of a simple pharmacological inhibitor such as SU5402. 
Contrastingly, if pERK does not show a decrease in downstream activation or signaling, 
even in the presence of an FGFR inhibitor, then FGF ligands may be acting on another 
receptor. Perhaps the dosage applied is so high that it is activating low-affinity receptors, 
which do not signal through ERK.  
Endogenous Heparin Sulfate levels may be insufficient in promoting a stable 
FGF-FGFR ligand-receptor complex (Ornitz and Itoh, 2001). A wide array of literature 
establishes the use of FGF ligand subtypes along with HS in treatment media, in order to 
mimic stabilization in vitro. The experiments could be repeated with larger 
concentrations of HS, with the expectation that it will stabilize FGF-FGFR complexes, 
and subsequently, promote downstream signaling.  
There may be highly localized phosphatases that act quickly in antagonizing 
phosphorylation of FGFR cytoplasmic domains (Alberts, 2008). Phosphatase inhibitors 
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could be added to the FGF drug treatments, in order to inhibit the antagonistic effects of 
these proteins. By allowing downstream activation to occur without disruption by 
phosphatases, downstream signaling may be potentiated. Furthermore, phosphorylation 
of the receptor kinase activity may be measured with the use of 32P-labeled adenosine 
triphosphate (ATP). Membrane preparations can be incubated with [γ-32P]ATP and FGF 
to stimulate auto-phosphorylation in the presence or absence of an inhibitor. After 
incubation, the reaction mixtures can be spotted onto filter paper, and washed to remove 
any unbound ATP. Receptor auto-phosphorylation may be detected with (1) scintillation 
counting, or (2) gel electrophoresis of reaction mixtures, followed by autoradiography. 
FGF receptor translocation to the plasma membrane may be disrupted, or 
contrastingly, receptors may be prematurely endocytosed. It is imperative to confirm the 
presence of FGFR on the plasma membrane, where the FGF-FGFR signaling complex 
potentiates FGF downstream signaling. Subcellular fractionation may be used to separate 
plasma membrane, nuclear membrane, and cytoplasmic cell fractions using centrifugation 
(Alberts, 2008). Plasma membrane fractions can be studied by Western blotting and 
tested for presence of FGFR1-4. Absent FGFRs would indicate that vesicle-mediated 
transportation is not properly occurring. Nuclear fractions may also be studied by 
Western blotting for the FGFR1-4; presence of receptors in this fraction may indicate that 
FGFR’s are being endocytosed and transported to the nucleus to pursue gene regulatory 
roles (Sørensen et al., 2006). Additionally, one could perform immunofluorescence 
staining with antibodies against FGFR1-4 then search for fluorescence at the borders of 
the cells. Furthermore, co-staining with antibodies against markers of plasma membrane 
and organelles such as the Golgi or late endosomes could reveal co-localization via 
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confocal microscopy. Antibodies must be raised in different species so secondary 
antibodies can be used with two different color fluorophores.  
Predetermined fate preceding the addition of FGFs may render hESCs 
incompetent in responding to FGF induction. Sequential qPCR studies are a feasible 
option to determine changes in expression levels of otic and non-otic placodal markers. 
By comparing Contextual Culture-treated hESCs and media-control hESCs, qPCR may 
reveal developmental changes underlying differential response to signaling molecules. It 
is possible that Contextual Culture-treated hESCs have committed to a less FGF-response 
fate before the addition of FGFs, resulting in reduced activation of ERK. To determine 
this, we would screen for markers of other tissues in addition to those of PPE, before FGF 
treatment. It is also possible that upon addition of FGFs, the cells up-regulate non-otic 
markers via other signaling pathways. Ultimately, it would be necessary to detect up-
regulation of Pax2 several days after the addition of FGFs in order to confirm that the 
cells follow an otic lineage.  
Perhaps the Western blotting assay for ERK downstream activation is not optimal 
in this system, due to a small pool of FGF-competent cells of PPE-character. qPCR to 
study the immediate transcriptional effects of FGF-FGFR activation is a potential, 
alternative readout for FGF signaling. The Sprouty family of antagonists of receptor 
tyrosine kinases has been shown to negatively regulate FGF signaling, in the context of 
otic placode specification (Zhang, 2014). qPCR could provide transcriptional readouts of 
Sprouty signaling in the Contextual Culture-treated hESCs as an additional avenue for 
assaying the downstream effects of FGF-FGFR signaling.  
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Furthermore, because the Validation Protocol Assays did not test the effects of 
FGF application on PPE-like cells, there may be natural biological variation that renders 
the Contextual Culture-treated cells incapable of responding to the translated 
experimental conditions. FGF dosage, duration and identity are variables of our protocol 
that depend on endogenous biological networks, which can change with differentiation. 
Dosage must be further elucidated; the 100 ng/mL “high” dose may not be high enough. 
By studying dose-response conditions on Contextual Culture-treated cells, a more 
effective FGF dose, and one that causes a biological phenomenon, may be discovered. It 
will be interesting to study how “high” is too “high,” in phosphorylating ERK. 
Additionally, Chen et al., (2012) has established a protocol that aims to optimize the early 
stages of otic specification in hESCs. This protocol for differentiation includes FGF3/10 
in the cell-culture media from the very beginning of treatment. In our Contextual Culture 
Paradigm, FGFs are added after the formation of the PPE. This time-course may involve 
FGF addition at a time too delayed, thus unfavorable, for the activation of downstream 
FGFR signaling. An earlier time-point, perhaps before PPE specification, might be key in 
inducing downstream activation; however, this would only be effective in otic 
specification if PPE formation remains undisturbed. The identity of FGFs necessary to 
activate signaling pathways in Contextual-hESCs may also be different. FGF3/10 has 
been implicated in formation of the inner ear (Alvarez et al., 2003), and this molecule 
may prove to be more efficient in activating ERK than the promiscuous FGF2, due to the 
otic context of the Contextual Culture Paradigm. Duration of FGF treatment is another 
experimental condition that must be further tested in the Contextual Culture Paradigm. 
As discussed above, as hESCs are searching for identity, it may be necessary to apply 
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FGF treatment for longer durations to provide cells with a long and strong enough signal 
that promotes FGF-FGFR interaction and signaling through downstream pathways. A 
duration-response experiment could yield promising results. 
Elucidating the role of cross-talk between canonical downstream pathways in otic 
specification is a long-term goal. The ERK pathway has been implicated in FGF-driven 
Pax2 up-regulation in the early stages of otic specification, upon the application of FGFs 
(Yang, 2013). Thus, the ERK pathway’s interactions with parallel pathways could be 
further studied by means of targeted inhibitors. It is well established that FGFRs can 
signal through all three pathways, ERK, AKT, and PLCγ, yet the role of AKT and PLCγ 
in otic development remains unclear. Additionally, since cross-talk between these 
pathways is known to occur, it is reasonable to propose that modulating AKT and PLCγ 
could have an effect on ERK-mediated up-regulation of Pax2. For example, Wang (2015) 
has proposed a model by which FGF-AKT signaling mediates otic neurogenesis, while 
FGFR-ERK signaling mediates otic sensorineurogenesis. This further strengthens the 
argument for focusing on the ERK pathway by inhibiting AKT and PLCγ. Perhaps PPE-
like cells may be guided to become otic progenitor-like instead of neuronal by blocking 
AKT signaling via an inhibitor molecule (Wang, 2015). Introducing inhibitors of ERK, 
AKT, PLCγ, and/or FGFR, may block or up-regulate the activation of parallel pathways 
in a combinatorial manner. As a further step, Western blotting for the activation of 
downstream pathways, upon addition of specific inhibitors, may be used in conjunction 
with qPCR to correlate expression changes with modulation of particular signaling 
pathways. In this way, new relationships and methods of cross-talk between pathways, in 
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an otic context, may be elucidated. This balanced network may be fine-tuned to mediate 
the up-regulation of otic markers, such as Pax2. 
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VII. Concluding Thoughts 
 
Our long-term goal remains to enhance the efficiency of hair cell differentiation from 
hESCs by systematically optimizing the small molecules essential for inner ear 
development. The central hypothesis for this study aimed to maximize targeted ERK 
activation through FGF signaling, in order to increase the efficiency of the early stages in 
hair cell differentiation. Recent literature motivated us to elucidate the roles of 
downstream canonical pathways, ERK, AKT, and PLCγ, which consist of the 
unidentified signaling pathways known to cooperate with FGFs. The Validation Protocol 
Assays allowed us to determine the experimental conditions necessary to detect 
biological activity of the downstream pathways, upon FGF application. However, 
translation of those experimental variables to the Contextual Culture Paradigm, a 
differentiation protocol directed toward otic specification, was not sufficient to induce 
biological activity in downstream pathways. There are several possible reasons for such 
results, and many future studies may be pursued to further elucidate the roles of FGF 
signaling and downstream targets, in an otic induction protocol.  
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VIII. Methods and Materials 
 
a. Methods 
Human ES Cell Culture  
H7 human ES cell cultures were maintained as described in Protocols. Briefly, hESCs 
were cultured on feeder-free Matrigel-coated plates and maintained in mTeSR medium. 
HESCs were passaged manually.  
 
Human Recombinant FGF2, FGF3, FGF10 Stock Solutions and Drug Treatments 
In a biosafety cabinet, FGF3 and FGF10 were made as 100 ug/mL stocks in PBS + 0.1% 
BSA. In experiments FGF3/10 were used together as 50 ng/mL each to give a total of 100 
ng/mL. FGF2 was made as a 100 ug/mL stock in PBS + 0.1% BSA and used as 100 
ng/mL. The drug treatments (detailed protocol in Appendix) which were applied to the 
EBs or monolayer cells, were made in their respective cell culture medium before being 
applied to the cells for the duration of treatment at 37°C in a 5% CO2 incubator. Treated 
cells were collected in 1X Laemmeli buffer, using a cell strainer, and they were either 
used in subsequent western blotting, or stored for western blotting in -20°C for a later 
time. 
 
Murine Recombinant PDGF-BB Stock Solutions and Drug Treatments 
The 25 ng/mL stocks were stored at -20°C. PDGF was used as 50 ng/mL or 25 ng/mL 
drug treatments made in PBS. The drug treatments (detailed protocol in Appendix) were 
applied to EBs and made in the EB formation medium before being applied to the cells 
for the duration of the treatment at 37°C in a 5% CO2 incubator. Treated cells were 
collected in 1X Laemmeli buffer, using a cell strainer, and they were either used in 
subsequent western blotting, or stored for western blotting in -20°C for a later time.  
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Statistical Analysis 
Data were analyzed with SPSS 21.0 to run single factor ANOVA with Tukey post-hoc 
comparisons. ANOVA was used because we were looking for differences in the sample 
means among several different groups (AggreWell, uncoated Sylgard, PEG, and 
pHEMA). Because we could not predict which groups would perform in more efficient 
EB formation than others, we did a Tukey post-hoc test. A p value of <0.05 with n=3 was 
considered statistically significant. EBs clearly fell into a bimodal distribution of sizes, 
thus we defined a boundary and analyzed the data for smaller-than or larger-than groups 
separately.  
 
Immunohistochemistry 
EBs (750 cells each) were allowed to attach to Matrigel overnight after harvest, and the 
cells were then fixed in 4% paraformaldehyde, blocked and permeabilized in phosphate-
buffered saline containing 0.1-0.4% Triton X-100. They were incubated with primary 
antibodies (Brachyury, Gata6, and Nestin) overnight at 4°C. After 24 hours, the attached 
EBs were incubated with fluorescent secondary antibodies for one hour at room 
temperature before being imaged on a Nikon TE-2000U microscope. 
 
Preparation of Sylgard Inserts 
AggreWellTM inserts were removed from the commercial plates, and the patterned surface 
was flooded with liquid 2% agarose. This combination was then inverted into a pool of 
agarose, and allowed to solidify. By removing the insert to leave a mold of the original 
pattern in the agarose, a negative cast of the AggreWellTM insert was made. The mold 
was filled with Sylgard 184, and a vacuum was applied to remove any bubbles in the 
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Sylgard mixture, as it sets into the negative cast of agarose. Placing a coverslip over this 
filling creates a flat bottom surface for the Sylgard insert. The Sylgard must then cure for 
48 hours at room temperature. Then it is gently released from the mold, peeled away 
from the coverslip, and any excess material is trimmed from around the edges. The 
inserts are sterilized by autoclaving, spraying 70% ethanol, and exposing to UV light. 
They are then fitted into sterile 24-well plates. To test various coating materials, the 
duplicated inserts were coated with poly(2-hydroxyethyl methacrylate) (pHEMA) in 95% 
ethanol overnight or with polyethylene glycol 8000 (PEG) in dH2O for one hour at room 
temperature. Then EB formation medium was added in order to wash out PEG by 
diluting with several changes of medium. 
 
Formation of EBs to Test Duplicate Inserts 
H7 hESCs were seeded into the mimicked wells at 300,000 per well for a target of 1,000 
cells per EB. Medium was supplemented with ROCK inhibitor at 10 uM. Cells were then 
spun into micro-wells and allowed to aggregate 48 hours in 37C incubator with 5% CO2. 
EBs were harvested by gentle pipetting and collected in low-attachment culture plates. 
Random, non-overlapping fields were imaged by light microscopy. ImageJ Program 
Software was used to process images, by measuring area, circularity, and aspect ratio of 
the EBs. 
 
Formation of H7 EBs for Short Protocol 
Each well was prepared with 6x105 cells (2,000 cells/well), and with gentle pipetting, 
cells were distributed evenly across each well as shown in the Short Protocol section. The 
plate was centrifuged at 100xg for three minutes, in order to capture the cells in the 
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micro-wells. There was a final volume of 2mL per well of EB formation medium 
(DMEM/F12 + 10% KOSR + 500 uM BME + NEAA) supplemented with ROCK 
inhibitor at 10 uM and SB431542. The plates were incubated at 37°C with 5% CO2 and 
95% humidity in the incubator for 48 hours.  
 
Harvesting EBs from Micro-well Plates 
EB formation medium was pre-warmed at room temperature. EBs were harvested from 
micro-wells by firmly pipetting in the well, up and down several times, with a 1 mL 
disposable tip. A 40 um cell strainer was used to separate EBs from single cells.  
 
Preplacodal Ectoderm Differentiation of H7 Monolayers 
H7 hESCs were dissociated with Trypsin incubation to single cells and re-suspended in 
mTeSR with 1:1000 ROCK inhibitor. The cells were counted and seeded as 200,000 
cels/well on madrigal-coated (6-well) plates, aiming for a density of 2x104/cm2, with 
mTeSR supplemented with ROCK inhibitor for a total volume of 1.5 mL/well. After 24 
hours, the media was changed to the Leung et. al 2014-inspired media [DMEM/F12 + 
N2(1x) + B27-Vitamin A(2x), NEAA(1x), Glutamax(1x), BME(0.1mM) + LDN (BMP 
inhibitor, 20 nM)]. This Leung-inspired media was changed every other day, and at Day 
8 FGF drug treatments were applied to the cells and assayed for downstream signaling as 
per the protocols listed in the “Protocols” section.  
 
Routine PCR for FGFR Detection and Quantitative PCR  
RNA was extracted for both routine and qPCR using Qiagen RNeasy Mini Kit, and the 
cDNA was prepped using SuperScript III Reverse Transcriptase. Intron-spanning PCR 
primers were designed against FGF Receptors 1-4. Expected bands: 294 bp (FGFR1), 
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363 bp (FGFR2), 276 bp (FGFR3), and 393 BP (FGFR4). The routine PCR primer pairs 
for each FGFR are listed in Methods and Materials. qPCR Probes are also listed in 
Materials and Methods. A 50 bp ladder was used for routine PCR. 
 
SDS-PAGE and Western Blot 
The protein samples were subjected to sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) on 4-15% (w/v) gels. The separated proteins were 
transferred onto PVDF or nitrocellulose membrane by suing a semidry electro-blotting 
apparatus (BioRad). Blotted proteins on the membrane were detected using either mouse 
or rabbit polyclonal primary antibodies, followed by the use of respective secondary 
antibodies. The blots were enhanced with chemiluminescence (either GE or PICO ECL), 
and visualized with an Alpha Innotech Fluorchem Imager.  
 
Western Blot Result Quantifications 
Activation of pathways was confirmed with antibodies against the phosphorylated and 
total forms of respective proteins in question; and the drug treatments were compared 
against the media controls, to calculate fold change. ImageJ software was used to 
quantify brightness of the Western blot bands upon visualization. Actin was used as a 
loading control, and all target protein signals are normalized against actin.   
 
Calculating Fold-Change 
ImageJ Software was used for image quantifications. Levels of pERK and tERK were 
measured via densitometry in ImageJ, and all Western blot bands were normalized to 
actin, used as a loading control. A [phosphorylated protein/total protein] ratio was 
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calculated and compared to media-only controls; in this way, fold-change was 
determined. 
 
b. Materials 
i. Reagents 
ROCK inhibitor, Y-27632 1mM stock (Millipore, cat. no. 688002) 
SB431542 (Sigma-Aldrich, cat. no. S4317) 
EB KnockOut Serum Replacement Media (KOSR) Media (Life Technologies, cat. no. 
10828-028) 
Trypan Blue (Sigma, cat. no. T8154) 
0.25% Trypsin-EDTA (1x) (Invitrogen, cat. no. 25200-056) 
Defined Trypsin inhibitor (Invitrogen, cat. no. R-007-100) 
FGF2 (Sigma, SRP4037) 
FGF3 (R&D Systems, cat. no. 1206-F3-025/CF) 
FGF10 (R&D Systems, cat. no. 345-FG-025/CF) 
DMEM/F12 (Invitrogen, cat. no. 11330-032) 
KOSR (Invitrogen, cat. no. 10828-028) 
BME (55 uM final) (Sigma, cat. no. M3148) 
MEM NEAA, 100X (Invitrogen, cat. no. ILT11140050) 
Sylgard 184 (Dow Corning) 
Agarose 2% (Invitrogen, cat. no. 16500-500)  
PEG 8000 (Gift from Corey Lab) 
pHEMA (Poly(2-hydroxyethylmethacrylate)) (Santa Cruz Biotechnology, cat. no. 
253284) 
SB431542 in solution (Stemgent, cat. no. 04-0010-05) 
Bovine Serum Albumin (BSA) (Life Technologies, cat. no. 15561-020) 
mTeSR (Stem Cell Technologies, cat. no. Catalog #05851) 
Dispase (Stem Cell Technologies, cat. no. 07923) 
Matrigel (Corning) 
RIPA Buffer (Sigma-Aldrich, cat. no. R0278) 
Protease Inhibitor (HaltTM, cat. no. PI78410) 
LDN-193189 in solution (Stemgent, cat. no. 04-0074-02) 
GlutaMax (Gibco, cat. no. 35050-079) 
PDGF-BB (PeproTech, cat. no. 315-18) 
PBS (Gibco, cat. no. 10010-023) 
SuperSignal West Pico (Thermo Scientific, cat. no. 34080) 
Amersham ECL (GE Healthcare, cat. no. RPN2235) 
Antibodies required for desired characterization (Table 1) 
Sodium pyruvate, 100 mM (Stemcell Technologies, cat. no. 07000) 
Paraformaldehyde (PFA, Electron Microscopy Sciences, cat. no. 15710) 
Stripping Buffer for Reprobing (Life Technologies, cat. no. 21059) 
Prestained Protein Marker, Broad Range (Cell Signaling Technology, cat. no. 7720) 
Ethidium Bromide (Sigma-Aldrich, cat. no. 1239-45-8) 
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2-Mercaptoethanol (Gibco, cat. no. 21985-023) 
B27 supplement minus Vitamin A (Gibco, cat. no. 12587-010) 
Blotting Grade Blocker Non Fat Dry Milk (BioRad, cat. no. 170-6404XTU) 
Tween™ 20 (Fisher BioReagents™, cat. no. 9005-64-5) 
Tris Buffered Saline (TBS), 10X Solution (Fisher BioReagents™, cat. no. 7447-40-7) 
 
Table 1. Antibodies, qPCR Probes, Routine PCR Primers 
Antibody Host Supplier Cat. No. Dilution 
Total ERK ½ 
(p44/42 MAPK) 
Rabbit Cell Signaling Technology 9012 1:1000 
Phospho-ERK ½ 
(Phospho-p44/42 
MAPK) 
Mouse Cell Signaling Technology 9016 1:500 
Total AKT Rabbit Cell Signaling Technology 9272 1:1000 
Phospho-AKT 
(Ser473) 
Rabbit Cell Signaling Technology 9271 1:1000 
Total PLCγ1 Rabbit Santa Cruz Biotechnology 1249 1:1000 
Phospho-PLCγ1 Rabbit Cell Signaling Technology 2821 1:1000 
Actin 
 
Rabbit Cell Signaling Technology 4967 1:1000 
Nestin  Millipore AB5922 1:200 
Gata6  Abcam AB22600 1:200 
Brachyury  R&D Systems AF2085 1:20 
Anti-Rabbit IgG Goat GE Healthcare NA934V 1:4000 
Anti-Mouse IgG Goat GE Healthcare NXa931 1:4000 
 
Table 2. qPCR Probes 
Probe Useful marker for Taqman Probe ID 
(Applied 
Biosystems) 
Nestin Lineage marker - Not a transcription factor but 
key to neural stem cells (ectoderm marker) 
Hs04187831_g1 
Gata6 Endoderm marker Hs00232018_m1 
TBX1 
(Brachyury) 
Mesoderm marker Hs00962556_m1 
Pax2 OEPD Marker Hs01057416_m1 
 
Table 3. Intron-Spanning Primers for Routine PCR 
Gene  Forward Primer Reverse Primer Product Size 
FGFR1 caaggtccgttatgccacct ttgtctgggccaatcttgct 294 bp 
FGFR2 accagaagtgtacgtggctg tggagccgcttttccatctt 363 bp 
FGFR3 agcaggagcagttggtcttc cgtcttcgtcatctcccgag 276 bp 
FGFR4 atggacaggcctttcatggg ggacctccacctctgagcta 393 bp 
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ii. Equipment 
AggreWell 800 plates (StemCell Technologies, cat. no. 27865 (1), 27965 (5)) 
Ultra-low attachment plate (6-well) (Corning, cat. no. 3471) 
Cell strainer, 40 uM (BD Falcon, cat. no. 352340) 
Hemacytometer 
35-mm Dishes (Corning, cat. no. CLS430588-500EA) 
Alpha Innotech FluorChem Imager 
5% CO2 Incubator 
Biosafety Cabinet 
Cell Filters (40 uM) 
BioRad Mini-PROTEAN® System  
BioRad Mini-PROTEAN® TGX Gels 4-15% (w/v) (BioRad, cat. no. 4561084) 
Cell Scrapers 
6-well plates 
15 mL conical tubes 
1.5 mL microtubes 
Millipore Amicon Protein Concentrator, 10kDa MW cutoff 
Qiagen RNeasy Mini Kit (Qiagen, cat. no. 74104) 
SuperScript III Reverse Transcriptase (Life Technologies, cat. no. 18080044) 
Route PCR Primers (Life Technologies, cat. no. A15612) (Table 3) 
50 bp PCR Ladder (Life Technologies, cat. no. 10416-014) 
Taqman Probes for qPCR (Applied Biosystems, cat. no. 433182) (Table 2) 
ImageJ Software 
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Appendices 
Appendix A: H7 HESC Maintenance and Passaging 
1) Warm media in a cabinet away from light at least 30 minutes prior to passaging.  
2) Aspirate media from wells.  
3) Add 1 mL Dispase per well.  
4) Incubate for 5 minutes at RT. Under a microscope, confirm that the cells have 
rounded and are detached from the surface of the plate. 
5) Wash with DMEM/F12 medium.  1 mL per well, at least 3 times. 
6) Add mTeSR medium (1 mL per well). Use 1 mL pipette tip and scratch. Avoid 
bubbles. Pick up the media and scratch while pushing out. If all cells are the same, 
the same pipette may be used across wells. Turn the plate 180 degrees to get the 
other side of the well from a better angle. Finally, transfer cells to a 15 mL tube. 
7) Use fresh media to rinse and obtain all cells. 1-2 mL is fine. 
8) Wait a few minutes for the large clumps to settle.  Differentiated cells are likely to 
be the smaller clumps at the top. 
9) Take premade Matrigel plates from the incubator. Aspirate the DMEM/F12 
media. Add 1.5 mL mTeSR per well. 
10) Aspirate off excess media from above the cells that have settled to the bottom of 
the tube, and replace (need for 0.5 mL/well). Tap tube to re-suspend. 
11) Add 0.5 mL of cells drop-wise, gently, to the Matrigel plate. 
12) Rock forward & back and side-to-side to mix. Label the plate, and replace it into 
the incubator. Remember to EtOH the plate before placing it in the incubator. 
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Appendix B: Preparing Sylgard Inserts 
1) Formation of the agarose negative 
a. Dissolve agarose in dH2O on a hot plate, spinning constantly, at 2% w/v. 
b. Place an AggreWell insert face-up in a 6-well plate, and fill the well 
halfway with liquid agarose. Moving quickly, spin bubbles out of the 
microwells with a 1-minute centrifugation at 2000 x g. 
c. Allow the agarose to set. 
d. Pipette a small amount of liquid agarose into a 35-mm dish. Use a spatula to 
transfer the agarose-filled insert micro-well side down into the liquid 
agarose. 
i. Ensure that the liquid agarose is not enough to cover the flat surface 
of the original insert. 
ii. The purpose of this additional agarose is simply to stabilize the mold 
within the 35-mm dish. 
e. Allow the agarose to set. 
f. Use forceps to loosen the insert and remove it from the agarose gently. 
When loosened enough, the insert may be removed by inverting the dish and 
gently tapping if necessary.  
2) Formation of Sylgard duplicate 
a. Prepare sylgard at 1:10 ratio by weight (curing agent is silicone). Mix 
thoroughly and spin 1-2 minutes at 2500 x g to remove bubbles. 
b. Pipette Sylgard into the agarose mold. Sylgard is highly viscous; cutting the 
end of a P1000 tip is helpful. Be careful not to introduce bubbles while 
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pipetting.  
c. Place the dish inside a vacuum dessicator and apply vacuum until bubbles 
rise to the top. 
i. To eliminate bubbles, blow air gently across the top surface.  
ii. May need to top off the Sylgard with a small volume to completely 
fill the mold. If so, it is not necessary to apply additional vacuum 
after this step. 
d. Carefully lower a square glass coverslip on top of the Sylgard, starting from 
one edge and then lowering the opposite edge to prevent trapping air. 
i. This will provide a flat, even surface for your duplicate insert. 
ii. Skipping this step may result in trapping cells and media underneath 
the insert and may impede imaging. 
e. Cover the dish, and wrap the edges with Parafilm. Allow molds to cure 48 
hours at room temperature. 
3) Preparing the duplicate for use  
a. Position forceps beneath the coverslip and any excess Sylgard. Find the 
border of the Sylgard; if it extends beyond the coverslip, then move the 
forceps beneath this border and beneath the coverslip. 
b. Lift up gently at several points around the insert to loosen it enough that the 
microwells begin visibly separating from the agarose. Once the insert is 
loose enough, it can be lifted away without damaging the agarose, if it is 
intended to reuse the mold. 
c. Wrap the used agarose mold with Parafilm, and store at 4C for future use.  
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Undamaged molds can be reused up to 3 times. 
d. Use a razor blade or “cookie cutter” to trim away any excess Sylgard from 
the duplicate and peel the duplicate away from the coverslip. Duplicates can 
be saved in a 60-mm dish at room temperature, away from light until use, or 
prepared further for immediate use. 
e. Autoclave 20 minutes, wrapped in foil. 
f. Spray thoroughly with 70% ethanol inside a tissue culture hood. Aspirate 
excess ethanol. 
g. Fit the insert into a well of a 24-well culture plate. 
h. Expose to UV light for 20 minutes to further sterilize.  
4) Coating with pHEMA (1 day prior to EB formation) 
a. Prepare 3% solution of pHEMA in 95% ethanol in dH2O. Dissolve by 
rotating 5-6 hours at 37°C. 
b. Apply 0.5 mL pHEMA solution to the insert. 
i. Check that no bubbles are trapped in the micro-wells. Due to the low 
surface tension of ethanol, this is typically not a concern.  
ii. If necessary, briefly spin the plate at 2000 x g to remove bubbles. 
iii. Allow plate to sit loosely covered inside culture hood overnight, 
undisturbed, with the fan turned off to allow the ethanol to evaporate 
and evenly deposit the pHEMA upon the insert surface.  
5) Coating with PEG (same day as EB formation) 
a. Prepare PEG 8000 10% w/v solution in dH2O. 
b. Filter sterilize using a 0.2 µm filter and syringe. 
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c. Apply 0.5 mL PEG solution to the insert. 
i. Briefly spin the plate at 2000 x g to remove bubbles. 
ii. Allow it to sit 1 hr at RT. 
iii. Wash out PEG by diluting with several changes of EB formation 
medium. 
6) Setting up EBs 
a. Set up EBs using the established protocol from STEMCELL Technologies. 
 
Appendix C: The Validation Protocol 
Media Components (KOSR media 10%, DMEM/F12, NEAA (1X), BME (0.1mM), 
SB431542 (10 uM), Y27632 (10 uM) 
 
a. Preparation of a Single Cell Suspension of Undifferentiated hESCs 
1) Add 0.2 mL 0.25% trypsin per well of 6-well plate.  Tip the plate to ensure 
coverage. 
2) Incubate 37°C ~4 minutes.  Tap the plate to ensure that the cells have loosened 
from the surface and that the colonies are breaking apart. 
3) Add 1.8 ml of media. 
4) Re-suspend by pipetting up and down with 1 mL tip approximately 8 times, or 
enough so that you have collected all cells from the surface and they are largely 
broken apart. 
5) Collect cells in a 15 mL tube.  Centrifuge the cells at 200 x g for 1.5 minutes at 
room temperature (15 - 25°C).  Aspirate the supernatant and resuspend the pellet 
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in a small volume of media.  As an estimate, use 1-2 mL per 6-well plate.  You 
want the concentration at ~ 0.5 - 1.0 x 106 cells/mL.   
6) Pipette the cells through a 40 uM filter (Catalog #27305).  Determine the volume 
of cells that run through the filter. 
7) Count cells. 
a. Add Trypan Blue to dilute the cells by 1:10 (e.g., 4 uL cells in 36 uL 
trypan blue) 
b. Count the 4 corners on both sides.  Pipette 10 uL onto each side of the 
hemacytometer. 
c. Calculation: Total cells counted on one side (or average of 2 sides) / 4 
squares / dilution factor 10 X 10,000 = cells per mL. 
I.e., ____________ / 4 X 10 X 10,000 = ____________ cells per mL. 
 
b. Formation of Human EBs Using AggreWell Plates 
Day 0 
1) Add 6x105 cells per well prepared with insert (2,000 cells per micro-well).  
Gently pipette several times to distribute evenly. 
2) Adjust to a final volume of 2 mL per well EB KOSR media. Gently pipette 
several times to re-establish an even distribution of cells. 
3) Centrifuge the plate at 100 x g for 3 minutes to capture the cells in the microwells.   
4) Examine the plate under a microscope to verify that cells are evenly distributed 
among the micro-wells. 
5) Incubate the cells at 37°C with 5% CO2 and 95% humidity for 48 hours. 
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c. Harvesting EBs from AggreWell Plates 
Day 2 
1) Pre-warm KOSR media. 
2) Harvest EBs from micro-wells by firmly pipetting media in the well up and down 
several times with a 1 mL disposable tip to dislodge most of the EBs.  If EBs are 
large, aseptically cut the tip off of a standard 1 mL tip to increase the bore size 
and prevent disruption of the EB. 
3) Separating the EBs from single cells: Use 40 um strainer.  Flow suspension 
through filter into a 50 mL waste tube.  EBs will remain on the filter.  Observe 
insert under microscope to ensure all EBs have been removed.  To collect any 
remaining EBs, wash the AggreWell surface with media, pipetting across the 
entire surface.  Pass this suspension through the filter. 
 
d. Assay for Downstream Pathway Activation 
Day 2 
1) For phosphorylation assays, invert the filter, centering the area where the EBs are 
concentrated over a 15 mL tube.  
2) Wash the EBs off the filter by passing 1 mL of media through.  Be certain you 
have recovered the full 1 mL of media so that your final drug concentration is 
accurate. 
3) Prepare drug treatments for FGF2 or FGF3/10 at required amount.  Stock is 100 
ug/mL in PBS + 0.1% BSA.  Make 1 mL per tube at 2X concentration so that 
when you add this to your EBs, you will dilute it to 1X final.  Drug treatments 
should be made at room temperature. 
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4) Also prepare PBS and 1X Laemmli buffer (stock is 2X, so dilute 1:1 with RIPA 
buffer).  Add phosphatase inhibitor to each (1X final from 100X stock).  Keep 
these on ice. 
5) Add drug treatments 1:1, and swirl or pipette gently to mix.  Be careful not to 
disturb them any more than required for mixing and quick handling as mechanical 
stimulation can confound pERK results. 
6) Keep caps loose, and place tubes into incubator. Incubate 37°C with 5% CO2 for 
5 minutes. 
7) Remove from incubator, and place tubes on ice. 
8) Remove drug treatment by pipetting gently so you don’t disturb the EBs, which 
should have settled to the bottom.  Add 1 mL PBS + phosphatase inhibitor as a 
wash. 
9) Spin EBs down gently to collect them (30 seconds at 200 xg should be sufficient). 
10) Place tubes on ice, and pipette off the PBS, being careful not to pick up EBs.  
Remove as much PBS as possible. 
11) Add Laemmli buffer (60 uL per tube).  Store at -20°C until ready to run gels. 
 
Appendix D: The Contextual Culture Paradigm Protocol 
Media Components: mTeSR, DMEM/F12, N2 (1X), B27 (Vit. A, 2X), NEAA (1X), 
Glutamax (1X), LDN (20 nM), (BME, 0.1 mM), Y27632 (10 uM) 
Day -1: 
1) Dissociate hESCs with Trypsin to single cells by applying 0.5 mL Trypsin/well. 
Incubate for 5 minutes in the 37°C CO2 incubator.  
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2) Stop trypsinization with 1.5 mL Trypsin Inhibitor and dissociate with a pipette 
about 10 times. Check under the microscope and pipet up and down two times 
while transferring to a 15 mL tube. 
3) Spine down cells for 5 min at 0.3 rcf. 
4) Re-suspend in mTeSR with 1:1000 ROCKi. 
5) Count and seed on Matrigel-coated (6-well) plates with mTeSR + ROCKi (1.5 
mL/well).  
Day 0: 
6) Change to Leung et. al medium (2 mL/well of a 6-well plate). 
Day 2 to Day 8: 
7) Change medium every other day.  
Day 8: 
8) Apply FGF drug treatments (this time included 1:1000 HS) to the cells and assay 
for downstream signaling as per the protocols listed above. 
 
Appendix E: Phosphorylation Assay for PDGF-Treated NIH3T3 Cells 
1) Serum starve 1 hour (see Pirkmajer and Chibalin, 2011, AJP Cell Physiology) in 2 
mL DMEM. 
2) Add 2 mL of each treatment (negative ctrl or PDGF) to the appropriate plate. 
3) Incubate 15 minutes with 37C. 
4) On ice, wash 1X with cold PBS + PI. 
5) Add 2 mL lysis buffer (41 uL protease inhibitor + 41 uL phosphatase inhibitor + 
4.2 uL sample + ↑4.1 mL final volume with RIPA) 
6) Wash 5 minutes, swirling. 
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7) Harvest in 1.7 mL tubes pre-chilled on ice (2 tubes per sample to accommodate 
the 2 mL).  Tip the flask to collect the sample, and pipette into your collection 
tubes.  Then go back over the flask with a cell scraper (following up with a 
pipette) to ensure you have collected everything. 
8) Incubate on ice an additional 30 minutes with occasional vortex. 
a. Sonication can help. Three pulses, 10 seconds each with 10 second rest 
between pulses, and use a low setting (~30% power).  Keep the samples 
on ice at all times to prevent the sonicator from heating the sample too 
much.  Keep the tip of the sonicator near the bottom of the tube but not 
touching the plastic.  Remember to use distilled water and a Kim-wipe to 
rinse and dry the sonicator tip before and after each sample. 
9) Spin 15 minutes 4C, 14000 x g. 
10) Since you have a large volume of lysate, you can use a protein concentrator.  Just 
know that you will lose proteins lower than the 10kDa MW cutoff.  Spin at 7500 
x g in fixed angle rotor 4C 10 minutes as per the product info. You will recover 
about 0.25 mL per sample from 2 mL original. Keep the portion from the top part 
of the concentrator, and discard the flow-through. Aliquot into smaller tubes, and 
store at -80C for later quantification. 
